ReviewDiscover oncology2026
Precision reirradiation in recurrent CNS tumors integrating biology techniques and multimodal care.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reirradiation has re-emerged as a viable salvage modality for recurrent central nervous system (CNS) tumors in the modern era of precision radiotherapy. Advances in image guidance, biological understanding of normal-tissue repair, and integration of targeted systemic agents have expanded its therapeutic window. The 2025 ISRS meta-analysis (62 studies; n = 2640) established a median overall survival (OS) of ~ 10.2 months after re-irradiation (re-RT) of recurrent HGG, confirming that focal single-fraction SRS (16 Gy × 1) or hypofractionated SRS (25 Gy/5 fx) achieves optimal tumor control with acceptable neurologic toxicity (7% vs 4%). EQD₂ > 120-130 Gy markedly increases radionecrosis risk (p = 0.003). Integration of DNA-damage-repair (DDR) inhibitors, VEGF blockade, and tumor-treating fields (TTFields) is under active investigation. Re-RT in ependymoma, meningioma, and spinal tumors is also gaining renewed interest with proton and MR-guided adaptive techniques.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.